International law firm Bird & Bird advised the funds Alven and Daphni in connection with their participation in the Series A funding round of Generare, a start-up specialising in the identification of new molecules through the exploration of bacterial genes, for an amount of €20 million.
This funding round, led by Alven and Daphni alongside existing investors Galion.exe, Teampact Ventures and VIVES Partners, will enable Generare to significantly expand its molecule portfolio and reach one thousand discoveries within two years. The company also aims to enter into its first exploitation licence in respect of one of its discoveries in the pharmacology and agriculture sectors.
Leveraging a technology that explores the 97% of natural products encoded in still-unexplored microbial genes, Generare has already identified 200 new molecules since its inception. The company, which currently employs around twenty people, had previously raised €5 million in a seed round in 2024.
Bird & Bird advised on the transaction with a team comprising partner Félicien Bardsley and associate Inès Louguar.
